1. Home
  2. HSCS vs KPRX Comparison

HSCS vs KPRX Comparison

Compare HSCS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSCS
  • KPRX
  • Stock Information
  • Founded
  • HSCS 2007
  • KPRX 1998
  • Country
  • HSCS United States
  • KPRX United States
  • Employees
  • HSCS N/A
  • KPRX N/A
  • Industry
  • HSCS Medical Specialities
  • KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • HSCS Health Care
  • KPRX Health Care
  • Exchange
  • HSCS Nasdaq
  • KPRX Nasdaq
  • Market Cap
  • HSCS 9.9M
  • KPRX 9.2M
  • IPO Year
  • HSCS 2022
  • KPRX N/A
  • Fundamental
  • Price
  • HSCS N/A
  • KPRX N/A
  • Analyst Decision
  • HSCS Strong Buy
  • KPRX Strong Buy
  • Analyst Count
  • HSCS 2
  • KPRX 1
  • Target Price
  • HSCS $10.50
  • KPRX $10.00
  • AVG Volume (30 Days)
  • HSCS 94.3K
  • KPRX 41.3K
  • Earning Date
  • HSCS 09-11-2025
  • KPRX 11-07-2025
  • Dividend Yield
  • HSCS N/A
  • KPRX N/A
  • EPS Growth
  • HSCS N/A
  • KPRX N/A
  • EPS
  • HSCS N/A
  • KPRX N/A
  • Revenue
  • HSCS $6,250.00
  • KPRX N/A
  • Revenue This Year
  • HSCS $13,968.97
  • KPRX N/A
  • Revenue Next Year
  • HSCS $166.67
  • KPRX N/A
  • P/E Ratio
  • HSCS N/A
  • KPRX N/A
  • Revenue Growth
  • HSCS N/A
  • KPRX N/A
  • 52 Week Low
  • HSCS $2.52
  • KPRX $2.25
  • 52 Week High
  • HSCS $6.47
  • KPRX $4.18
  • Technical
  • Relative Strength Index (RSI)
  • HSCS 53.94
  • KPRX 59.99
  • Support Level
  • HSCS $3.57
  • KPRX $2.67
  • Resistance Level
  • HSCS $3.80
  • KPRX $2.89
  • Average True Range (ATR)
  • HSCS 0.17
  • KPRX 0.12
  • MACD
  • HSCS 0.02
  • KPRX 0.02
  • Stochastic Oscillator
  • HSCS 62.50
  • KPRX 79.32

About HSCS Heart Test Laboratories Inc.

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: